ATE498684T1 - Adiponectin-promoter und verwendung davon - Google Patents
Adiponectin-promoter und verwendung davonInfo
- Publication number
- ATE498684T1 ATE498684T1 AT03768257T AT03768257T ATE498684T1 AT E498684 T1 ATE498684 T1 AT E498684T1 AT 03768257 T AT03768257 T AT 03768257T AT 03768257 T AT03768257 T AT 03768257T AT E498684 T1 ATE498684 T1 AT E498684T1
- Authority
- AT
- Austria
- Prior art keywords
- syndrome
- dna
- screening method
- transformants
- human adiponectin
- Prior art date
Links
- 102000011690 Adiponectin Human genes 0.000 title 1
- 108010076365 Adiponectin Proteins 0.000 title 1
- 208000011580 syndromic disease Diseases 0.000 abstract 5
- 238000012216 screening Methods 0.000 abstract 3
- 101000775469 Homo sapiens Adiponectin Proteins 0.000 abstract 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 206010020852 Hypertonia Diseases 0.000 abstract 1
- 102000004877 Insulin Human genes 0.000 abstract 1
- 108090001061 Insulin Proteins 0.000 abstract 1
- 208000001145 Metabolic Syndrome Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000002498 deadly effect Effects 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 102000057799 human ADIPOQ Human genes 0.000 abstract 1
- 208000020346 hyperlipoproteinemia Diseases 0.000 abstract 1
- 229940125396 insulin Drugs 0.000 abstract 1
- 210000001596 intra-abdominal fat Anatomy 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000003449 preventive effect Effects 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/80—Vector systems having a special element relevant for transcription from vertebrates
- C12N2830/85—Vector systems having a special element relevant for transcription from vertebrates mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Obesity (AREA)
- General Engineering & Computer Science (AREA)
- Physics & Mathematics (AREA)
- Heart & Thoracic Surgery (AREA)
- Endocrinology (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Food Science & Technology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2002376589 | 2002-12-26 | ||
| PCT/JP2003/016772 WO2004058970A1 (ja) | 2002-12-26 | 2003-12-25 | アディポネクチンプロモーターおよびその用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE498684T1 true ATE498684T1 (de) | 2011-03-15 |
Family
ID=32677368
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03768257T ATE498684T1 (de) | 2002-12-26 | 2003-12-25 | Adiponectin-promoter und verwendung davon |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US7585623B2 (de) |
| EP (1) | EP1577388B1 (de) |
| JP (1) | JP4744882B2 (de) |
| AT (1) | ATE498684T1 (de) |
| AU (1) | AU2003292822A1 (de) |
| DE (1) | DE60336076D1 (de) |
| WO (1) | WO2004058970A1 (de) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7741080B2 (en) | 2004-03-31 | 2010-06-22 | Nissan Chemical Industries, Ltd. | Adiponectin expression-inducing agents and uses thereof |
| KR100610219B1 (ko) | 2004-07-30 | 2006-08-10 | 한국생명공학연구원 | 아디포넥틴 프로모터를 포함하는 벡터에 의해 형질전환된 세포를 이용한 세포신호 전달물질의 검색방법 |
| ATE508191T1 (de) | 2006-11-01 | 2011-05-15 | Medical Res And Infrastructure Fund Of The Tel Aviv Sourasky Medical Ct | Adipozytenspezifische konstrukte und verfahren zur hemmung der expression von blutplättchen-typ- 12-lipoxygenase |
| JP5030579B2 (ja) * | 2006-12-26 | 2012-09-19 | 三菱レイヨン株式会社 | ロドコッカス属細菌用発現ベクター |
| EP2020447A1 (de) | 2007-08-03 | 2009-02-04 | Zeltia, S.A. | Verfahren zur Identifizierung von Adiponectin-Genexpressions-modulierenden Verbindungen |
| CN113671196B (zh) * | 2021-07-29 | 2023-09-12 | 中国人民解放军空军军医大学 | Lair-1分子与脂联素的相互作用对于t细胞活化作用影响的研究方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1127120B1 (de) | 1998-11-04 | 2008-05-28 | Serono Genetics Institute S.A. | Genomische und vollständige cdna sequenzen von menschlichem adipozyten spezifischem apm1 und biallelische marker davon |
| JP2000236886A (ja) * | 1998-12-24 | 2000-09-05 | Takeda Chem Ind Ltd | Ｕｃｐ−２プロモーターおよびその用途 |
| US7445890B1 (en) * | 1998-12-24 | 2008-11-04 | Takeda Pharmaceutical Company Limited | Ucp-2 promoter and use thereof |
| JP2001054386A (ja) * | 1999-08-17 | 2001-02-27 | Takeda Chem Ind Ltd | ヒトプロラクチン放出ペプチド受容体遺伝子プロモーターおよびその用途 |
| WO2002083726A2 (en) | 2001-04-10 | 2002-10-24 | Genfit | A novel zinc finger protein and uses thereof |
-
2003
- 2003-12-25 US US10/540,864 patent/US7585623B2/en not_active Expired - Lifetime
- 2003-12-25 WO PCT/JP2003/016772 patent/WO2004058970A1/ja not_active Ceased
- 2003-12-25 DE DE60336076T patent/DE60336076D1/de not_active Expired - Lifetime
- 2003-12-25 EP EP03768257A patent/EP1577388B1/de not_active Expired - Lifetime
- 2003-12-25 AT AT03768257T patent/ATE498684T1/de not_active IP Right Cessation
- 2003-12-25 AU AU2003292822A patent/AU2003292822A1/en not_active Abandoned
- 2003-12-25 JP JP2004562943A patent/JP4744882B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1577388B1 (de) | 2011-02-16 |
| US7585623B2 (en) | 2009-09-08 |
| DE60336076D1 (de) | 2011-03-31 |
| JP4744882B2 (ja) | 2011-08-10 |
| US20060084618A1 (en) | 2006-04-20 |
| JPWO2004058970A1 (ja) | 2006-04-27 |
| EP1577388A1 (de) | 2005-09-21 |
| WO2004058970A1 (ja) | 2004-07-15 |
| AU2003292822A1 (en) | 2004-07-22 |
| EP1577388A4 (de) | 2006-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69809558D1 (de) | Auswahlmethode für potentielle mittel gegen fettleibigkeit, zur regulierung des ucp-2 | |
| WO2005059106A3 (en) | Interferon alpha antibodies and their uses | |
| IL178226A (en) | Use of @@ antibody @ anti @ ngf @ to make @cure @ to treat @ pain @ cancer | |
| NO20054769D0 (no) | Substituerte fenylalkansyrer | |
| ATE432072T1 (de) | Verwendung von adapalen zur behandlung dermatologischer erkrankungen | |
| BRPI0606992A2 (pt) | análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis | |
| AU2003234529A8 (en) | Glp-1 gene delivery for the treatment of type 2 diabetes | |
| RU2017104800A (ru) | Способы лечения пациентов с гетерозиготной семейной гиперхолестеринемией (hefh) | |
| Vaverková et al. | Inverse association of lipoprotein (a) with markers of insulin resistance in dyslipidemic subjects | |
| MXPA05011524A (es) | Acidos carboxilicos sustituidos. | |
| TW200630327A (en) | Substituted phenylalkanoic acids | |
| DE60336076D1 (de) | Adiponectin-promoter und verwendung davon | |
| ATE359087T1 (de) | Verwendung von erythropoietin zur behandlung oder vorbeugung von herzversagen | |
| Rives‐Lange et al. | Seventy years of bariatric surgery: A systematic mapping review of randomized controlled trials | |
| Pal et al. | Self-assembling nano-globular peptide from human lactoferrin acts as a systemic enhancer of bone regeneration: A novel peptide for orthopedic application | |
| EP3927817C0 (de) | Neue rekombinante diaminoxidase und deren verwendung zur behandlung von durch überschüssiges histamin charakterisierten krankheiten | |
| YU73301A (sh) | eNOS MUTACIJE,NJIHOVA UPOTREBA ZA PRIPREMU LEKA ZA GENSKU TERAPIJU I POSTUPCI TERAPEUTSKOG SKRININGA | |
| DE60015508D1 (de) | C-16 ungesätigte fp-selektive prostaglandin analoge | |
| EA200601120A1 (ru) | N-арилпиперидинзамещённые бифинилкарбоксамиды в качестве ингибиторов аполипопротеина в | |
| EP1757302A8 (de) | Adiponectin-expressionsinduktor und seine verwendung | |
| Rhee et al. | Maintenance of Increased Bone Mass After Recombinant Human Parathyroid Hormone (1‐84) With Sequential Zoledronate Treatment in Ovariectomized Rats | |
| Yoon et al. | Moonlighting activity of secreted inflammation-regulatory proteins | |
| Torrero et al. | New developments in the treatment of osteoarthritis–focus on biologic agents | |
| TW200631949A (en) | Substituted carboxylic acids | |
| Jahn et al. | Increased beta2-adrenergic signaling is a targetable stimulus essential for bone healing by promoting callus neovascularization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |